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Abstract
Background: The lectin-like oxidized LDL receptor LOX-1 (encoded by OLR1) is believed to play a key role in
atherogenesis and some reports suggest an association of OLR1 polymorphisms with myocardial infarction (MI). We
tested whether single nucleotide polymorphisms (SNPs) in OLR1 are associated with clinically significant CAD in the
Atherosclerotic Disease, VAscular FuNction, & Geneti C Epidemiology (ADVANCE) study.
Methods: ADVANCE is a population-based case-control study of subjects receiving care within Kaiser Permanente of
Northern California including a subset of participants of the Coronary Artery Risk Development in Young Adults
(CARDIA) study. We first resequenced the promoter, exonic, and splice site regions of OLR1 and then genotyped four
single nucleotide polymorphisms (SNPs), including a non-synonymous SNP (rs11053646, Lys167Asn) as well as an
intronic SNP (rs3736232) previously associated with CAD.
Results: In 1,809 cases with clinical CAD and 1,734 controls, the minor allele of the coding SNP was nominally associated
with a lower odds ratio (OR) of CAD across all ethnic groups studied (minimally adjusted OR 0.8, P = 0.007; fully adjusted
OR 0.8, P = 0.01). The intronic SNP was nominally associated with an increased risk of CAD (minimally adjusted OR
1.12, p = 0.03; fully adjusted OR 1.13, P = 0.03). However, these associations were not replicated in over 13,200
individuals (including 1,470 cases) in the Atherosclerosis Risk in Communities (ARIC) study.
Conclusion: Our results do not support the presence of an association between selected common SNPs in OLR1 and
the risk of clinical CAD.
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Background
Oxidized LDL (oxLDL) is thought to play a crucial role in
the initiation of atherosclerotic lesions. The lectin-like
oxidized LDL receptor (LOX-1) is expressed on endothe-
lial cells, macrophages and vascular smooth muscle cells
and specifically binds and internalizes oxLDL leading to
pleotropic effects on endothelial dysfunction and athero-
sclerosis. LOX-1 was originally identified by Sawamura et
al [1] and was later localized to chromosome 12. The
human gene spans six exons and encodes a protein of 273
amino acids with four distinct domains: an N-terminal
cytoplasmic domain crucial for cell sorting, a transmem-
brane domain, a neck domain with homology to the
myosin heavy chain, and a C-terminal lectin-like domain
(CTLD) which is responsible for binding oxLDL [2-5]
(Figure 1). In vitro, oxLDL binding to LOX-1 results in
increased expression of cellular adhesion molecules,
inflammatory mediators and activation of pro-apoptotic
pathways [6-10]. In vivo, LOX-1 is found at high concen-
trations in human atherosclerotic lesions and overexpres-
sion of LOX-1 in apolipoprotein E -/- mice results in
increased cholesterol deposition in coronary arteries
[11,12].
Human association studies to date have been conflicting
regarding whether polymorphisms in this gene are associ-
ated with CAD and/or its complications [13-21]. As part
of the overall goals of the Atherosclerotic Disease, VAscu-
lar FuNction, & Geneti C Epidemiology (ADVANCE)
study at Stanford University and Kaiser Permanente of
Northern California (KPNC), we sought to test whether
SNPs in the LOX-1 gene, ORL1, alter susceptibility to
CAD. We also sought to replicate any putative genotype-
phenotype associations in an independent and well char-
acterized cohort as replication is now considered the gold
standard method to validate such associations [22,16,23-
27]. We selected the National, Heart, Lung, and Blood
Institute's Atherosclerosis Risk in Communities (ARIC)
study to serve as our replication cohort because the pri-
mary outcome of interest in that study of incident coro-
nary heart disease (CHD) was the same as the ADVANCE
study and was diligently adjudicated.
Methods
Study Sample ADVANCE
The ADVANCE study included adults (age ≥18 years)
receiving medical care within KPNC. Detailed description
of the eligibility criteria and the source population for all
cohorts, have been published previously [28-30]. The
design of ADVANCE allowed for several primary case con-
trol comparisons (see study website for details[31]).
Between October 28, 2001 and December 31, 2003, we
recruited a total of 3179 case and control subjects. Cases
consisted subjects presenting with clinically significant
CAD (myocardial infarction or angina with angiogram
showing at least one > 50% stenosis) at a young age (< 45
years for males, < 55 years for females) or subjects present-
ing with incident stable angina or incident acute myocar-
dial infarction (AMI) at an older age. Controls consisted
of young subjects with no history of CAD including a sub-
set of 479 subjects from the Coronary Artery Risk Devel-
opment in Young Adults (CARDIA) Study [32], or
subjects aged 60 to 72 with no history of CAD, cerebrov-
ascular accident (CVA), or peripheral arterial disease
(PAD). During recruitment, some race/ethnic and gender
strata were oversampled to maximize the probability that
case and control groups were balanced in these respects.
In this study, we focused on a combined analysis compar-
ing subjects with symptomatic early onset CAD ("young
cases") with young subjects without CAD ("young con-
trols") and older subjects presenting with stable angina or
AMI ("older cases") with older subjects with no history of
CAD, CVA, or PAD ("older controls") (Table 1).
Clinical Measurements
Through a phone interview, an extensive self administered
questionnaire, and the use of the KPNC electronic data-
bases, we documented the presence or absence and age of
onset of clinically significant CAD, CVA, and PAD, as well
as all traditional risk factors for atherosclerosis. Subjects
also provided information on race/ethnicity and were
classified into one of nine race/ethnic groups: white/Euro-
peans, black/African Americans, Hispanics, South Asians,
East Asians, Pacific Islanders, Native Americans, admixed
Hispanics, and admixed non-Hispanics. At the clinic visit,
we measured the height and weight of all participants and
collected whole blood for DNA extraction and quantifica-
tion of various serum markers. For this study, traditional
Structure of LOX-1 gene and protein Figure 1
Structure of LOX-1 gene and protein. Upper drawing: 
Rectangles represent exons, with tic marks & arrows desig-
nating location of sequenced SNPs and genotyped SNPs in 
the ADVANCE study respectively. Lower drawing: Sche-
matic of the protein structure of LOX-1. The arrow shows 
the position of LOX 1.2 SNP, and the resultant amino acid 
change.
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risk factors (smoking, hypertension, high cholesterol, and
diabetes) were defined based on self report and were con-
sidered to be present only if subjects reported an age of
onset of a risk factor that was younger than the age of
onset of clinically significant CAD.
Sequencing & Genotyping
Using an automated fluorescent labeling system [33], we
resequenced the promoter region, the exons including the
5' and 3' untranslated regions (UTRs), and the intron-
exon boundaries of OLR1 in 24 ethnically diverse males
with a history of CAD (SNP discovery set). A subset of all
SNPs identified by sequencing was then genotyped in all
participants of the ADVANCE study using the TaqMan®
assay. In addition, a random sample of approximately
15% of all genotyped SNPs was genotyped in duplicate.
The discrepancy rate among all SNPs that were either
sequenced and genotyped or genotyped in duplicate was
0.002%. We were unable to make a genotype call in only
0.35% of the samples. For LOX1.2 and LOX1.3 the refer-
ence strand used for the determination of the minor allele
was chosen to be consistent with dbSNP convention.
Information on all SNPs from the SNP discovery effort has
been submitted to the national dbSNP database.
The subset of sequenced SNPs for genotyping in all study
participants using the TaqMan® assay [33] was selected on
the basis of the minor allele frequency observed in the
SNP discovery set, the predicted functional effect, and the
degree of linkage disequilibrium between SNPs. In gen-
eral, we prioritized for genotyping SNPs with a higher
MAF (to maximize statistical power), SNPs in exonic or
promoter regions (to maximize the probability of a func-
tional effect). When possible, we genotyped SNPs not in
strong linkage disequilibrium (LD) with each other to try
to identify as many haplotypes as possible across our
regions of interest. All resequencing and genotyping was
performed by the Stanford Human Genome Center.
Table 1: Non-genetic characteristics of the ADVANCE study according to case/control status (symptomatic CAD) stratified by two 
primary predefined comparisons
Young Cases (n = 
472)
Young Controls (n 
= 742)
P Older Cases (n = 
1337)
Older Controls (n 
= 992)
P
Mean(SD) Mean(SD) T test Mean(SD) Mean(SD) T test
Age(years) * 45.3(6.5) 44.3(5.5) 0.005 62(8.4) 65.8(2.9) <0.001
Median (Range) Median (Range) Wilcoxon Median (Range) Median (Range) Wilcoxon
Body Mass Index 31.1 (17.3–61.2) 26.8 (15.8–66.2) <0.001 28.4 (16.9–66.1) 27.5 (17.3–52.9) <0.001
C-Reactive Protein 2.3 (0.1–76.4) 1.2 (0.1–76.8) <0.001 1.7 (0.1–77.4) 1.6 (0.1–73.9) 0.163
Months from first ever 
event to study visit
21.3 (2.7–222.1)† -- -- 3.5 (1.4–26.4)† -- --
Count(%) Count(%) Chi2 Count(%) Count(%) Chi2
Risk Factors (Self 
Report)
Male 184(39) 328(44.2) 0.072 975(72.9) 618(62.3) <0.001
Current/Former 
smoker
276(58.5) 266(35.8) <0.001 842(63) 569(57.4) 0.006
Hypertension 154(32.6) 143(19.3) <0.001 641(47.9) 407(41) <0.001
Diabetes Mellitus 101(21.4) 51(6.9) <0.001 274(20.5) 147(14.8) <0.001
High Cholesterol 129(27.3) 148(19.9) 0.003 604(45.2) 356(35.9) <0.001
Ancestry <0.001 <0.001
White/European 254(53.8) 369(49.7) 947(70.8) 677(68.2)
Black/African 
American
46(9.7) 254(34.2) 50(3.7) 79(8)
Hispanic 25(5.3) 22(3) 83(6.2) 60(6)
East Asian 44(9.3) 35(4.7) 73(5.5) 68(6.9)
Admixed Hispanic 32(6.8) 23(3.1) 52(3.9) 31(3.1)
Admixed Non-
Hispanics
71(15) 39(5.3) 132(9.9) 77(7.8)
Age was defined at first ever event for cases, study visit date for controls. The age cutoff for a "young case" was not the same for males (<45 years) 
and females (<55 years). †P < 0.001 for Wilcoxon test.BMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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Statistical Analysis
We excluded from further analysis subjects who did not
provide blood for DNA extraction (n = 40) and who did
not fill out the study questionnaire (n = 9). We also
excluded South Asians (n = 55) because of a lack of con-
trols. Lastly, we excluded Pacific Islanders (n = 9) and
Native Americans (n = 2) because of small numbers.
For each set of cases and controls, we compared the distri-
butions and frequencies of all non-genetic covariates of
interest using standard parametric and non-parametric
methods. For each race/ethnic group, we calculated minor
allele frequencies of all SNPs genotyped in all participants
and tested for Hardy-Weinberg equilibrium (HWE) with
the permutation version of the exact test [34]. Using mul-
tivariate unconditional logistic regression, we then calcu-
lated odds ratios (ORs) for symptomatic CAD associated
with the minor allele for each of the three traditional
modes of inheritance (recessive, additive, dominant). All
ORs were first adjusted for age, gender, self-reported race/
ethic group, and source of cases and controls (young set vs
old set) and then further adjusted for BMI, smoking status
(ever versus never), hypertension, diabetes, and hyperlip-
idemia. To minimize the probability of confounding due
to population substructure in our 'Admixed Hispanic' and
'Admixed Non-Hispanic' race/ethnic groups, we esti-
mated the proportion of white/European, black/African-
America, Hispanic and East Asian ancestry at the individ-
ual level for all cases and controls in these groups and
used these estimates as covariates in our fully adjusted
analyses[35]. For each SNP, we also tested for the presence
of heterogeneity among the ORs across all race/ethnic
groups and both set of cases and controls using appropri-
ate interaction terms in the co-dominant logistic model.
For LOX1.2 and LOX1.3, we calculated the power of our
study sample to detect the odds ratios we observed for that
SNP. For these calculations, we assumed the polymor-
phism was causal, a population prevalence of sympto-
matic CAD of 6.2% [36] and a Type 1 error of 0.05.
We used SAS v 9.1.3 including the SAS genetics module v.
2.2, STRUCTURE[35], and the genetic power calculator
[37], to carry out all analyses.
Replication in the ARIC Study
To avoid reporting spurious findings, it is necessary to rep-
licate putative associations in an independent cohort [22].
Study participants were selected from the ARIC Study, a
prospective investigation of atherosclerosis and its clinical
sequelae involving 15,792 individuals from four commu-
nities aged 45–64 years at recruitment (1987–1989). A
detailed description of the ARIC Study design and meth-
ods have been published previously [38-43]. Incident cor-
onary heart disease (CHD) cases were defined as definite
or probable MI, a silent MI between examinations by
ECG, a definite CAD death or coronary revascularization.
Genotyping the LOX1.2 SNP (Lys167Asn) was performed
using the TaqMan Assay (Applied Biosystems, Foster City,
CA) (primers available on request). The LOX1.3 SNP was
assayed using a pre-made, validated assay from ABI (assay
ID C-3130875-).
Follow-up was available until December 31, 2002. Time-
to-event was analyzed using Cox proportional hazards
modeling. We adopted the methods of Hsieh and Lavori
[44] to calculate post-hoc the minimal detectable hazard
ratio based on the standard deviation of genotypes where
homozygote major equals 0, heterozygote equals 1 and
homozygote minor equals 2.
We used STATA, and PASS [45] to carry out all analyses in
the ARIC study.
Consent and Institutional Review Board Approval
The ADVANCE study was approved by the Institutional
Review Boards (IRBs) at Stanford, the Kaiser Foundation
Research Institute and the Palo Alto Veterans Administra-
tion Hospital. The ARIC study was approved by all partic-
ipating institutional IRBs. All subjects in both the
ADVANCE and ARIC studies gave written informed con-
sent.
Results
Non-genetic covariates of interest in ADVANCE
The study population consisted of 3,543 subjects (1,809
cases and 1,734 controls). The prevalence of most tradi-
tional risk factors of atherosclerosis was significantly
greater in cases than in controls (Table 1). The lower prev-
alence of males in the younger case/control set and the
younger age of cases in the older case/control set were the
result of stratified sampling. Stratified sampling and/or
preferential participation also led to differences in the
prevalence of certain race/ethnic groups.
LOX1 SNP discovery
We identified 16 SNPs by sequencing the promoter
region, the exons and flanking intronic regions of OLR1 in
the 24 subjects of different ethnic groups from our SNP
discovery set (Figure 1). In the promoter region, our SNP
discovery primer set started approximately 620 bp 5' from
the transcription start site. Three of these SNPs had minor
allele frequencies (MAFs) of 2% and were not analyzed
further. The remaining SNPs had MAFs of 20% or greater
over all race/ethnic groups, and of these SNPs LOX 1.1
(rs2742112), LOX 1.2 (rs11053646), LOX 1.3
(rs3736232) and LOX 1.16 (rs1050286) were selected for
genotyping in all participants in the ADVANCE study.
Minor allele frequencies for these SNPs are shown in
Table 2.BMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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Association analysis in ADVANCE
We found no evidence of heterogeneity of the ORs across
race/ethnic groups and the two sets of cases and controls
("younger" versus "older") for the additive logistic model
(details not shown). Therefore, in Tables 3 and 4, we only
present the OR for each inheritance model across both
sets of cases and controls only stratified by race/ethnic
group and combined across race/ethnic groups.
The LOX 1.1 SNP in the promoter region of the gene was
not associated with clinical CAD. However, the "C" allele
of the LOX 1.2 SNP (G501C leading to Lys167Asn) was
associated with a decreased risk of CAD (MAF of 8.8% in
1808 cases and 11.9% in 1731 controls, fully adjusted OR
0.8, P = 0.01). This association was also significant in a
dominant model but not in a recessive model (Table 3).
There was no major difference in the OR between the
younger set and older set of cases and controls (additive
model fully adjusted ORs 0.74, CI 0.55–1.01, p = 0.06 and
0.82, CI 0.67–1.02, P = 0.07 for younger and older case/
control set respectively). The "C" allele of the LOX 1.3
SNP was weakly associated with an increased risk of CAD
in the combined analysis (MAF of 44.7% in cases and
39.8% in controls, fully adjusted model OR 1.13, P =
0.03) (Table 4). An association with CAD was also present
for the recessive model of this SNP (fully adjusted OR
1.32, P = 0.004) but not for a dominant model. There was
no major difference in the OR between the younger set
and older set of cases and controls (additive model fully
adjusted ORs 1.08, CI 0.88–1.32, p = 0.46 and 1.15, CI
1.01–1.32, P = 0.03 for younger and older case/control set
respectively). As LOX 1.3 and LOX 1.16 SNPs were found
to be in near perfect linkage disequilibrium (details not
shown), the results of the association analyses for the LOX
1.16 were essentially identical to LOX1.3 (details not
shown).
We performed additional analyses using only the subset
of young and old cases presenting with AMI [see Addi-
tional file 1]. The results for both SNPs (LOX1.2 and
LOX1.3) are not substantially different in any of the three
models (recessive, additive or dominant either minimally
or fully adjusted) whether cases include all subjects with
clinically significant CAD versus cases presenting with MI.
While the point estimates for the odds ratios are quite
similar there is a loss of significance in the MI comparison
presumably because of a decrease in power caused by
excluding subjects with incident angina. For instance,
LOX 1.2 in our overall analysis has a fully adjusted, addi-
tive model OR 0.8 (0.68–0.95, P < 0.05) for the "clinically
significant CAD vs control" as compared to an OR 0.84
(0.69–1.02, P = 0.07) for the "MI vs control" comparison.
Similar results were found for LOX 1.3 (OR 1.13, 1.0–
1.25, P < 0.05 vs 1.08, 0.96–1.22, P = 0.19).
For the least common LOX-1 SNP across all race/ethnic
groups combined (LOX1.2), the minimal detectable ORs
was 1.2 for an additive model assuming that the minor
allele increases risk and 0.71 assuming the minor allele
decreases risk.
Replication in ARIC
Non-genetic characteristics of the ARIC sample are sum-
marized in Table 5. Genotype counts in the ARIC cohort
for LOX 1.2 and LOX 1.3 are summarized in Table 6.
LOX1.2 was genotyped in a total of 9,858 white and 3,367
African American individuals and the LOX 1.3 SNP was
genotyped in 9,844 white and 3,359 African American
individuals. After stratification by race, all race/ethnic spe-
cific genotype counts were in HWE with the exception of
LOX 1.3 which showed some evidence of deviation from
HWE in African American subjects (P < 0.01). The MAFs
for these SNPs were very similar to that seen in the
ADVANCE cohort.
Table 6 also summarizes hazard rate ratios (HRR) for
symptomatic CHD for the minor allele of each SNP. For
LOX1.2, neither the minimally adjusted nor the fully
Table 2: SNPs in the LOX-1 gene that were genotyped in ADVANCE subjects
SNP Name dbSNP Type Change Minor/Major 
Allele
Minor Allele Freq (%)
White/
European
Black/African 
American
East Asian Hispanic
LOX1.1 rs2742112 5' 391 5' transc start A/G 31 46 57 39
LOX1.2 rs11053646 exon mRNA 563, 
Lys-Asn
C/G 9 20 16 6
LOX1.3 rs3736232 intron 26 3' exon 4 C/G 49 20 23 49
LOX1.16 rs1050286 exon 3' UTR G/A 49 23 23 50
Bold indicates non-synonymous amino acid change. For association analysis, the minor allele is defined as the least prevalent allele across both sets 
of controls in all race/ethnic groups combined.BMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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adjusted models demonstrated an association with inci-
dent CHD. For LOX1.3, the minor allele showed a nomi-
nally significant association with clinical CHD but in the
opposite direction than that seen in the ADVANCE study
(HRR 0.92, P = 0.04 for the additive model).
We also performed analyses in ARIC in subjects present-
ing with "incident MI + fatal CHD" as well as "incident
non-fatal MI" (see Additional file 1). The results do not
differ substantially from those using "incident CHD". For
these three comparisons (incident CHD, incident MI +
fatal CHD, incident non-fatal MI) the overall HRR, CI and
P values in fully adjusted additive model for LOX 1.2 are:
0.99, 0.9–1.1, NS; 0.98, 0.9–1.1, NS; 0.98, 0.8–1.2, NS
and for LOX 1.3 are: 0.92, 0.9–1.0, P = 0.04; 0.88, 0.8–1.0,
P = 0.01; 0.91, 0.8–1, NS.
The minimal detectable HRR in the ARIC study for
LOX1.2 SNP was estimated to be 1.17 for an additive
model assuming the minor allele increases risk and 0.85
assuming the minor allele decreases risk.
Discussion
Oxidized LDL plays a key role in the initiation of athero-
sclerotic lesions. As an endothelial receptor for oxLDL,
LOX-1 has been shown to initiate pro-atherogenic cas-
cades and is an attractive candidate gene for CAD suscep-
tibility [2,4-10,46]. We sought to determine whether SNPs
in the LOX-1 gene, OLR1 are associated with CAD. In our
discovery sample (ADVANCE), we found nominally sig-
nificant associations of a non-synonymous coding SNP
(LOX 1.2) and an intronic SNP (LOX 1.3) with clinical
CAD. However, we were unable to replicate these findings
in an independent sample (the ARIC study) with ade-
Table 3: Genotype counts and ORs for LOX 1.2 in the ADVANCE study combining both sets of cases and controls
Recessive Additive Dominant
Genotype Cases N 
(%)
Controls N 
(%))
minimal 
model
fully 
adjusted 
model
minimal 
model
fully 
adjusted 
model
minimal 
model
fully 
adjusted 
model
LOX1.2 OR
CI
OR
CI
OR
CI
OR
CI
OR
CI
OR
CI
White GG 1034 (86) 842 (80)
GC 154 (13) 194 (19) 1.44
0.6–3.6
1.59,
0.6–4.0
0.75**
0.6–0.9
0.76*
0.6–0.95
0.69**
0.6–0.9
0.7**
0.6–0.9
CC 12 (1) 9 (1)
Black/AA GG 65 (68) 201 (61)
GC 30 (31) 118 (36) 0.25
0.01–1.4
0.23
0.01–1.3
0.8
0.5–1.3
0.77
0.47–1.2
0.85
0.5–1.4
0.82
0.5–1.4
CC 1 (1) 12 (3)
Hispanic GG 96 (89) 73 (89)
GC 12 (11) 9 (11) 1
NA
1
NA
1.05
0.4–2.9
1.18
0.4–3.4
1.05
0.4–2.9
1.18
0.4–3.4
CC 0 (0) 0 (0)
E. Asian GG 90 (77) 66 (64)
GC 23 (20) 33 (32) 1.02
0.2–4.9
1.94
0.2–4.8
0.61
0.4–1.0
0.56*
0.3–0.98
0.49*
0.3–0.9
0.45*
0.2–0.97
CC 4 (3) 4 (4)
Mix. Hisp. GG 72 (86) 48 (89)
GC 11 (13) 6 (11) 3E+09
NA
8E+08
NA
1.66
0.6–5.5
1.51
0.5–5.3
1.64
0.5–5.6
1.51
0.46–5.3
CC 1 (1) 0 (0)
Mix. other GG 150 (74) 92 (79)
GC 53 (26) 21 (18) 0*
NA
0*
NA
1.32
0.8–2.3
1.28
0.73–2.3
1.6
0.9–3.0
1.56
0.8–3.0
CC 0 (0) 3 (3)
All GG 1507 (83) 1322 (76)
GC 283 (16) 381 (22) 0.8
0.41–1.5
0.8
0.41–1.5
0.8**
0.7–0.9
0.8*
0.7–0.95
0.77**
0.6–0.93
0.78**
0.7–0.94
CC 18 (1) 28 (2)
OR = Odds ratio, ref = reference group, NA = unable to compute, All P values < 0.05 in bold, * P < 0.05, ** P < 0.01.
† combined analyses adjusted for race/ethnic group and case/control set
Minimal model adjusted for age, sex. Fully adjusted analyses adjusted for age, sex, BMI, smoking status, hypertension, diabetes, high cholesterol, 
"admixed" strata further adjusted for proportion of white, black, Hispanic, E. Asian ancestry derived from STRUCTURE analyses. Non-stratified 
analyses further adjusted by race/ethnic group and cases/control status.BMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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quate power to detect the risk ratio observed in the discov-
ery sample.
Previous human genetic association studies of the LOX1.2
variant (G501C) have yielded conflicting results [13-
15,21]. Recently, Morgan et al. were not able to show an
association of this SNP with acute coronary syndrome in
a study of over 1,400 white subjects [16]. Although the
predicted amino acid change (Lys167Asn) occurs in the
α1 helix in a region called the "acid-base patch" that
might be important for secondary binding of oxLDL [4,5],
to our knowledge, there are no reports detailing the effect
of the Lys167Asn on oxLDL binding.
Mango et al. studied both the G501C SNP as well as a
group of SNPs in introns (rs3736232, rs3736234,
rs3736235, rs17174597, rs13306593) and the 3'UTR
(rs1050283) of OLR1 that were in very strong LD with one
another. They found that these non-coding SNPs were
highly associated with MI, the OR for MI for carriers of the
minor allele at the 3'UTR was 3.7 [14]. This group has
recently shown that this group of non-coding SNPs regu-
lates the production of a splice variant of LOX-1 (termed
LOXIN), which results in a less robust response to oxLDL
and decreased apoptotic signaling. Carriers of the minor
alleles of these non-coding SNPs produce less LOXIN, and
thus may be at increased risk of CAD [47]. We did geno-
type one of the SNPs identified by Mango et al. (LOX 1.3,
rs3736232) and also found that presence of the minor
"C" allele was associated with CAD. However, our efforts
to replicate this finding in ARIC were not successful.
In CAD alone, many initially positive reports have not
withstood the test of replication in other cohorts The rea-
Table 4: Genotype counts and ORs for LOX 1.3 in the ADVANCE study combining both sets of cases and controls
Recessive Additive Dominant
Genotype Cases N 
(%)
Controls N 
(%))
minimal 
model
fully 
adjusted 
model
minimal 
model
fully 
adjusted 
model
minimal 
model
fully 
adjusted 
model
LOX1.3 OR
CI
OR
CI
OR
CI
OR
CI
OR
CI
OR
CI
White GG 290 (24) 269 (26)
GC 603 (51) 560 (54) 1.29*
1.1–1.6
1.3*
1.1–1.6
1.13
1.0–1.3
1.13
1.0–1.3
1.08
0.88–1.3
1.08
0.88–1.3
CC 301 (25) 216 (20)
Black/AA GG 55 (58) 223 (67)
GC 30 (31) 90 (27) 2.31
0.92–5.6
2.5
0.95–6.3
1.47
0.99–2.2
1.49
0.99–2.2
1.49
0.89–2.5
1.49
0.88–2.5
CC 10 (11) 18 (6)
Hispanic GG 43 (30) 20 (24)
GC 45 (45) 41 (50) 1.02
0.5–2.1
0.76
0.34–1.7
0.92
0.6–1.4
0.85
0.53–1.4
0.78
0.38–1.6
0.85
0.39–1.8
CC 19 (25) 21 (26)
E. Asian GG 65 (56) 64 (62)
GC 44 (38) 35 (34) 2.26
0.6–10
2.56
0.64–12
1.26
0.78–2.0
1.25
0.76–2.1
1.2
0.67–2.2
1.16
0.04–2.1
CC 7 (6) 4 (4)
Mix. Hisp. GG 21 (25) 11 (21)
GC 39 (46) 31 (58) 1.39
0.6–3.7
1.45,
0.59–3.7
1.02,
0.59–1.7
1.04
0.6–1.8
0.73
0.29–1.8
0.76
0.3–1.9
CC 24 (29) 11 (21)
Mix. other GG 87 (43) 49 (44)
GC 79 (39) 48 (43) 1.01
0.5–2.1
0.98
0.47–2.1
0.42
0.64–1.4
0.93
0.63–1.4
0.85
0.49–1.5
0.86
0.5–1.5
CC 35 (18) 14 (13)
All GG 570 (32) 636 (37)
GC 847 (47) 805 (47) 1.3*
1.1–1.6
1.32**
1.1–1.6
1.12*
1.0–1.2
1.13*
1.0–1.25
1.06
0.9–1.25
1.07
0.9–1.25
CC 380 (21) 284 (16)
OR = Odds ratio, ref = reference group, NA = unable to compute, All P values < 0.05 in bold, * P < 0.05, ** P < 0.01
† combined analyses adjusted for race/ethnic group and case/control set
Minimal model adjusted for age, sex. Fully adjusted analyses adjusted for age, sex, BMI, smoking status, hypertension, diabetes, high cholesterol, 
"admixed" strata further adjusted for proportion of white, black, Hispanic, E. Asian ancestry derived from STRUCTURE analyses. Non-stratified 
analyses further adjusted by race/ethnic group and cases/control statusBMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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sons for the frequent failure of candidate gene studies to
date to detect robust associations have been widely
reviewed [16,48-53].
As in all population genetic studies, the probability of
reporting a false negative finding exists. This probability
increases significantly in underpowered studies. A key
strength of this report is the large number of cases and
controls enrolled in the ADVANCE study and the large
number of participants in the ARIC study. Thus, based on
our power estimates for each study, it is unlikely that we
missed a large effect.
Our study has several limitations. First, the ADVANCE
study did not enroll cases that either died or were too ill
to participate at any time after their incident event and
prior to the clinic visit. It is difficult to predict what effect,
if any, this selection bias may have had on our observed
ORs. Regardless, this selection bias was not present in the
ARIC cohort study, which captured incident fatal events.
Second, the ARIC study did not have many cases with an
age of onset in the same age range as the young cases in
the ADVANCE study. Because genotypic effects on CAD
risk are generally expected to be greater in subjects with
early onset disease [54], a reasonable argument could be
made that our inability to replicate associations in the
ARIC study was a consequence of a paucity of early onset
cases in that cohort. However, the ARIC study still had
adequate power to detect the OR noted in the ADVANCE
late onset cases and controls for both LOX1.2 and
LOX1.3. Furthermore, the nominally significant HRR for
LOX1.3 in the opposite direction of the ADVANCE study
serves as further compelling evidence that the initial find-
ing was a false positive. Third, because we did not geno-
type all possible variants or tag SNPs we cannot be certain
that other common allelic variants of this gene are not
associated with CAD. Based on HapMap data, at least 8
tagged SNPs in white/Europeans and 14 tagSNPs in Afri-
can Americans (r2 between all SNPs in a bin of ≥ 0.8, min-
imum minor allele frequency of 1%) would have to be
genotyped in this gene to efficiently capture all common
haplotypes [55]. However, we did genotype the only vali-
dated coding SNP in OLR1.
Conclusion
Large well-powered allelic association studies have great
potential for identification of CAD susceptibility genes.
The LOX 1.2 and LOX 1.3 SNPs are particularly attractive
because the mechanism for risk modification is plausible.
We found tentative associations for these SNPs in the
ADVACE study. However, all studies like ADVANCE have
statistical limitations due to multiple comparisons. To
prevent spurious associations, the accepted standard for
such analyses is independent replication in another
cohort [48-50,56]. We attempted to replicate our findings
in the ARIC study, a large community based study of the
genetics of atherosclerosis in whites and African Ameri-
cans. Putative associations must be replicated in multiple
large cohorts before they can be assumed to be real. Thus,
the overall set of analyses does not support an association
between these SNPs and CAD.
Table 5: Characteristics of Incident Coronary Heart Disease cases and non-cases in the Atherosclerosis Risk in Communities cohort, 
stratitifed by race
Whites African Americans
Cases Non-Cases Cases Non-Cases
(n = 1,168) (n = 8,802) (n = 319) (n = 3,119)
Mean (SEM) Mean (SEM) P** Mean (SEM) Mean (SEM) P**
Age (years)† 55.7 (0.2) 53.9 (0.06) <0.0001 55 (0.3) 53.1 (0.1) <0.0001
Age at event (years) 63.9 (0.2) -- 63.0 (0.4) --
Body Mass Index (kg/m2)† 27.8 (0.1) 26.8 (0.05) <0.0001 30 (0.3) 29.5 (0.1) 0.1
HDL Cholesterol (mg/dL)† 42.8 (0.4) 52.2 (0.2) <0.0001 48.6 (0.8) 56.0 (0.3) <0.0001
Total Cholesterol (mmol/L)† 5.82 (0.03) 5.5 (0.01) <0.0001 5.84 (0.07) 5.51 (0.02) <0.0001
%% P * * %% P * *
Males 69.4 42.2 <0.001 49.5 35.9 <0.001
Diabetes† 20.2 6.6 <0.001 34.2 16.4 <0.001
Hypertension† 38.6 23.7 <0.001 72.7 52.1 <0.001
Smoking† 31.4 23.6 <0.001 42 27.9 <0.001
SEM = Standard error of the mean
*P-value comparing means or proportions between cases and non-cases
†At the baseline visitBMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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Table 6: Allele frequencies and Hazard Rate Ratios for incident CAD for minor alleles of LOX 1.2, LOX 1.3 in the Atherosclerosis Risk 
In Communities study
Recessive Additive Dominant
geno Cases Non-cases model 1 model 2 model 1 model 2 model 1 model 2
counts (%) counts (%) HR
CI
HR
CI
HR
CI
HR
CI
HR
CI
HR
CI
LOX 1.2
Whites GG 938 (81) 7075 (81)
CG 204 (18) 1549 (18) 1.22
0.7–2.1
1.23
0.7–2.1
1.01
0.88–1.2
0.99
0.86–1.1
1
0.86–1.2
0.97
0.84–1.1
CC 14 (1) 78 (1)
Total 1156 8702
AA GG 185 (59) 1841 (60)
CG 118 (38) 1056 (35) 0.72
0.4–1.3
0.79
0.4–1.4
1
0.83–1.2
0.98
0.8–1.2
1.05
0.84–1.3
1.01
0.8–1.3
CC 11 (3) 156 (5)
Total 314 3053
All GG 1123 (76) 8916 (76)
CG 322 (22) 2065 (18) 0.95
0.64–1.4
1.0
0.7–1.5
1.01
0.9–1.1
0.99
0.88–1.1
1.01
0.9–1.1
0.99
0.88–1.1
CC 25 (2) 234 (2)
Total 1470 11755
LOX1.3
Whites GG 342 (30) 2393 (27)
GC 560 (48) 4329 (50) 0.93
0.81–1.1
0.93
0.81–1.1
0.93
0.86–1.0
0.94
0.87–1.0
0.9,
0.8–1.0
0.91
0.8–1.0
CC 250 (22) 1970 (23)
Total 1152 8692
AA GG 236 (74) 2099 (69)
GC 72 (23) 818 (27) 0.79
0.4–1.5
0.93
0.5–1.8
0.81
0.65–1.0
0.85
0.68–1.1
0.78
0.6–1.0
0.81
0.63–1.0
CC 10 (3) 124 (4)
Total 318 3041
All GG 578 (39) 4492 (38)
GC 632 (43) 5147 (44) 0.92
0.8–1.1
0.93
0.81–1.1
0.92*
0.85–0.99
0.92*
0.86–1.0
0.87*
0.78–0.97
0.89*
0.79–0.99
CC 260 (18) 2094 (18)
Total 1470 11733
Model 1: adjusted for age and gender (and race in non-stratified analyses).
Model 2: adjusted for age, gender, center, HDL and total cholesterol, BMI, smoking, diabetes and hypertension status (and race in non-stratified 
analyses). * P < 0.05BMC Medical Genetics 2008, 9:23 http://www.biomedcentral.com/1471-2350/9/23
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